Open an account

Valneva SE

VALN · NYSE

$5.26−$0.10 (−1.87%)TodayMarket closed ·
Prev close $5.36

About VALN

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 694 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Employees
694
Headquarters
Saint-Herblain, Pays De La Loire
Listed
Jun 28, 2007
Sector
Health Care
Industry
Biotechnology
Website
valneva.com

VALN key statistics

Market cap
469.28M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
27.49K
Volume
6.41K
Open price
$5.30
High today
$5.30
Low today
$5.25
52 Week high
$12.18
52 Week low
$4.75

Valneva SE (VALN) at a glance

Valneva SE (VALN) last traded at $5.26, with a market cap of 469.28M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.25 and $5.30. The current price is 0.2% above the day's low and 0.7% below its high.

Volume so far is 6.41K shares, below the average of 27.49K shares a day.

Over the past year Valneva SE has ranged from $4.75 to $12.18, and now sits 7% of the way up that range.

Valneva SE met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.17 per share against an estimate of -$0.101.

VALN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 57.3% on average.

  1. Q3 FY24: reported -$0.07 per share against an estimate of -$0.1465
  2. Q4 FY24: reported -$0.25 per share against an estimate of -$0.1162
  3. Q1 FY25: reported -$0.06 per share against an estimate of -$0.1616
  4. Q2 FY25: reported -$0.07 per share against an estimate of -$0.1616
  5. Q3 FY25: reported -$0.26 per share against an estimate of -$0.1364
  6. Q4 FY25: reported -$0.29 per share against an estimate of -$0.2121
  7. Q1 FY26: reported -$0.18 per share against an estimate of -$0.0707
  8. Q2 FY26: reported -$0.17 per share against an estimate of -$0.101

VALN news

  • Full Transcript: Valneva Q2 2026 Earnings Call

  • Vandana Singh

    UK Revokes Approval for Valneva's Chikungunya Shot

  • Avi Kapoor

    Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

  • Vandana Singh

    European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application

  • Avi Kapoor

    Dow Falls Over 100 Points; US Consumer Sentiment Declines In August

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

  • Press releaseBusiness Wire

    Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.